Contact Us
Drug Search Results
More Filters [+]

Bococizumab

Alternative Names: bococizumab, pf-04950615, rn316
Latest Update: 2023-12-01
Latest Update Note: PubMed Publication

Product Description

Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. (Sourced from: https://www.nejm.org/doi/full/10.1056/nejmoa1701488)

Mechanisms of Action: PCSK9 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Bococizumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Myocardial Infarction|Stroke|Obstetric Labor, Premature|Angina, Stable|Angina, Unstable|Hyperlipidemia|Hyperlipoproteinemia Type II|Hypercholesterolemia|Angina Pectoris|Dyslipidemia|Hyperlipoproteinemias|Atherosclerosis

Phase 2: Hypercholesterolemia|Dyslipidemia|Hyperlipidemia

Phase 1: Dyslipidemia|Lipid Metabolism Disorders|Hypercholesterolemia|Hyperlipidemia|Hyperlipoproteinemias|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
SPIRE-ASIA

P3

Withdrawn

Dyslipidemia|Hyperlipidemia|Hyperlipoproteinemias

2019-05-03

B-HIVE

P3

Terminated

Dyslipidemia

2017-11-01

SPIRE-2

P3

Terminated

Obstetric Labor, Premature|Stroke|Myocardial Infarction|Angina, Stable|Angina, Unstable|Hyperlipidemia

2017-04-03

JapicCTI-142485

P2

Completed

Hypercholesterolemia

2017-03-31

Recent News Events

Date

Type

Title

12/01/2023

PubMed

 Population PK/PD modeling of low-density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti-PCSK9 monoclonal antibody.

09/02/2023

PubMed

 Anti-drug Antibody Magnitude and Clinical Relevance Using Signal to Noise (S/N): Bococizumab Case Study.

01/31/2023

News Article

 Outlook on the Angina Pectoris Treatment Global Market to 2030 - by Drug Class and Region

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions